Newborn Screening for Adrenoleukodystrophy

NCT02952482 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45796

Last updated 2018-07-12

No results posted yet for this study

Summary

To test if the routine newborn screening dried blood spots can be used to test if elevation of C26:0 lysophosphatidylcholine (C26:0-lyso-PC), a status indicating adrenoleukodystrophy (ALD)

Conditions

  • Adrenoleukodystrophy

Interventions

PROCEDURE

newborns testing for ALD

Routine newborn screening dried blood spots sample is used to test if elevation of C26:0-lyso-PC

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Eligibility

Min Age
2 Days
Max Age
3 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-08-31
Completion
2017-08-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02952482 on ClinicalTrials.gov